Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis.
Journal Information
Full Title: Ther Clin Risk Manag
Abbreviation: Ther Clin Risk Manag
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Health Care Sciences & Services
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure S.L. is a Consultant and/or Advisor for Adaptive Biotechnologies, Alexion Therapeutics, Bristol-Meyers-Squibb, Caelum Biosciences, Janssen Pharmaceuticals, Karyopharm Therapeutics, Oncopeptides AB, GSK, Abbvie, Janssen, Pfizer, and Takeda Pharmaceutical Company; receives research funding from Celgene, Inc., Sanofi, Zentali; received honoraria from Clinical Care Options and Regeneron Pharmaceuticals; and has Royalties/Patents with Caelum Biosciences. In addition, S.L. has a patent CAEL-101 with royalties paid to Columbia University. The authors report no other disclosures or conflicts of interest in this work."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025